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http://www.ehoonline.org/content/3/1/19CORRECTIONCorrection: Survival and hospitalization among
patients with acute myeloid leukemia treated
with azacitidine or decitabine in a large managed
care population: a real-world, retrospective,
claims-based, comparative analysis
B Douglas Smith1†, Charles L Beach2, Dalia Mahmoud3†, Laura Weber3 and Henry J Henk4*†After the publication of this work [1], it was brought to
our attention that a statement in the article is not con-
sistent with the data. The statement “Prior RBC transfu-
sions were found to significantly increase the time to
hospitalization (adjusted HR 1.373, p = 0.018) while no
other covariates examined were found to impact the risk
of hospitalization” is not a correct reflection of the re-
sults from the data analysis in Table 2 of the article.
The corrected statement is provided here as follows:
“Prior RBC transfusions were found to significantly
shorten the time to hospitalization (adjusted HR 1.373,
p = 0.018) while no other covariates examined were
found to impact the risk of hospitalization.”
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